Please assess the completion status of the following clinical trial:

Trial Title: Stanford Regulating Circuits of the Brain Study- Ketamine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ages 18-55 years~* At least 2 prior uses of ketamine when aged 18+~* BMI within healthy range (18-30)~* Ability to speak, read, or understand English~Exclusion Criteria:~* Current active suicide ideation or history of suicide attempts~* Current mood, anxiety, eating, psychotic, or substance use disorder~* Lifetime psychotic or bipolar disorder~* Schizophrenia in a first degree relative~* Current use of psychotropic medication~* Prior adverse ketamine response~* Allergy or hypersensitivity to ketamine~* Use of ketamine in past 7 days~* Cannabis use in the past 7 days, illicit recreational drug use in the 48 hours prior to sessions, and/or alcohol use in the 24 hours prior to sessions~* Concurrent use of any medications that might increase the risk of participation (e.g., drug interactions)~* History of epilepsy, convulsions, seizures, LOC \>10 min~* Renal/hepatic impairment~* Hypertension (Stage 1 defined as systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg on 2 of 3 measurements at least 15 min apart at initial screening; systolic blood pressure \>155 mmHg or diastolic blood pressure \>99 mmHg on 2 of 3 measurements at least 15 min apart during infusion visits)~* Heart rate \<50 bpm or \>150 bpm at initial screening~* Chronic congestive heart failure, tachyarrhythmias, myocardial ischemia assessed via EKG at initial screening~* EKG QTcF intervals \>430 ms for men and \>470 ms for women~* Direct physical access to or routine handling of addicting drugs in the regular course of work duties~* MRI contraindication~* Pregnant or nursing females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: None

Study Arms:
- Volunteers (Type: None): Participants will receive an IV infusion of ketamine (\~.05mg/kg and 0.5mg/kg) or placebo.~Ketamine is an FDA-approved dissociative anesthetic. The study doses are in the subanesthetic range. During the infusion, an ACLS-certified psychiatrist or anesthesiologist will provide continuous monitoring.~Afterwards, patients will be monitored on-site by an ACLS-certified MD or highly skilled research nursing staff, and an on-call emergency response team for 4 hours (ketamine's half-life is 15 min; 4 hrs= 16 half-lives).

Based on this trial design, predict the completion outcome and termination type (if applicable).